Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells

Journal of Drug Targeting

Volumn 15, Issue 6, 2007, Pages 399-406

  Baum, Patrick ^a   Müller, Dafne ^a   Rüger, Ronny ^b   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Active targeting; Fibroblast activation protein; Immunoliposomes; Single chain Fv; Tumor stroma

Indexed keywords

CELL PROTEIN; CYSTEINE; DRUG; FIBROBLAST ACTIVATION PROTEIN; IMMUNOLIPOSOME; LIGAND; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STROMA CELL; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CROSS REACTIONS; DRUG CARRIERS; DRUG STABILITY; ENDOSOMES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; LIPOSOMES; MEMBRANE PROTEINS; MICE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SERINE ENDOPEPTIDASES; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447499944     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701453034     Document Type: Article

References (35)

1. Aertgeerts, K., Levin, I., Shi, L., Snell, GP, Jennings, A., Prasad, GS, Zhang, Y., Kraus, ML, Salakian, S., Sridhar, V., Wijnands, R. and Tennant, MG (2005) Structural and kinetic analysis of the substrate specifcity of human fibroblast activation protein α. J Biol Chem, 280, pp. 19441-19444.
2. Albini, A. and Sporn, MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer, 7, pp. 139-147.
3. Bauer, S., Adrian, N., Williamson, B., Panousis, C., Fadle, N., Smerd, J., Fettah, I., Scott, AM, Pfreundschuh, M. and Renner, C. (2004) Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol, 172, pp. 3930-3939.
4. Bhowmick, NA, Neilson, EG and Moses, HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature, 432, pp. 332-337.
5. -/- knock-out mouse. Mol Med, 7, pp. 461-469.
6. De Wever, O. and Mareel, M. (2003) Role of tissue stroma in cancer cell invasion. J Pathol, 200, pp. 429-447.
7. Dolznig, H., Schweifer, N., Puri, C., Kraut, N., Rettig, WJ, Kerjaschki, D. and Garin-Chesa, P. (2005) Characterization of cancer stroma markers: In silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immunity, 5, pp. 1-9.
8. Garin-Chesa, P., Old, LJ and Rettig, WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA, 87, pp. 7235-7239.
9. Gerspach, J., Müller, D., Münkel, S., Selchow, O., Nemeth, J., Noack, M., Petrul, H., Menrad, A., Wajant, H. and Pfizenmaier, K. (2006) Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ, 13, pp. 273-284.
10. Hofheinz, R-D, al-Batran, S-E, Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H. and Stehle, G. (2003) Stromal antigen targeting by a humanised monoclonal antibody: An early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie, 26, pp. 44-48.
11. Iden, DL and Allen, TM (2001) In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta, 1513, pp. 207-216.
12. Joyce, JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell, 7, pp. 513-520.
13. Kalluri, R. and Zeisberg, M. (2006) Fibroblasts in cancer. Nat Rev Cancer, 6, pp. 392-401.
14. Kelly, T. (2005) Fibroblast activation protein-a and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updates, 8, pp. 51-58.
15. Kirpotin, DB, Drummond, DC, Shao, Y., Shalaby, MR, Hong, K., Nielsen, UB, Marks, JD, Benz, CC and Park, JW (2006) Antibody targeting of long-circulating lipidic naoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res, 66, pp. 6732-6740.
16. Kontermann, RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther, 8, pp. 39-45.
17. Lee, J., Fassnacht, M., Nair, S., Boczkowski, D. and Gilboa, E. (2005) Tumor immunotherapy targeting fibroblast activation protein, a product expressed tumor-associated fibroblasts. Cancer Res, 65, pp. 11156-11163.
18. Liotta, LA and Kohn, EC (2001) The microenvironment of the tumour-host interface. Nature, 411, pp. 375-379.
19. Loeffler, M., Krüger, JA, Niethammer, AG and Reisfeld, RA (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest, 7, pp. 1955-1962.
20. de Menezes, DE Lopes, Pilarski, LM and Allen, TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res, 58, pp. 3320-3330.
21. Marty, C., Odermatt, B., Schott, H., Neri, D., Ballmer-Hofer, K., Klemenz, R. and Schwendener, RA (2002) Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B firbonectin scFv a ntibody modified liposomes. Br J Cancer, 87, pp. 106-112.
22. Mastrobattista, E., Koning, GA and Storm, G. (1999) Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev, 40, pp. 103-127.
23. Park, JE, Lenter, MC, Zimmermann, RN, Garin-Chesa, P., Old, LJ and Rettig, WJ (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem, 274, pp. 36505-36512.
24. Park, JW, Kirpotin, DB, Hong, K., Shalaby, R., Shao, Y., Nielsen, UB, Marks, JD, Papahadjopoulos, D. and Benz, CC (2001) Tumor targeting using anti-HER2 immunoliposomes. J Control Release, 74, pp. 95-113.
25. Park, JW, Hong, K., Kirpotin, DB, Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, UB, Marks, JD, Moore, D., Papahadjopoulos, D. and Benz, CC (2002) Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 8, pp. 1172-1181.
26. Park, JW, Benz, CC and Martin, FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol, 31, pp. 196-205.
27. Pastorino, F., Brignole, C., Paolo, D Di, Nico, B., Pezzolo, A., Marimpietri, D., Pagnan, G., Piccardi, F., Cilli, M., Longhi, R., Ribatti, Corti, A., Allen, TM and Ponzoni, M. (2006) Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res, 66, pp. 10073-10082.
28. Rettig, WJ, Garin-Chesa, P., Beresford, HR, Oettgen, HF, Melamed, MR and Old, LJ (1988) Cell-surface glycoproteins of human sarcomas: Differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci USA, 85, pp. 3110-3114.
29. Rettig, WJ, Garin-Chesa, P., Healey, JH, Su, SL, Ozer, HL, Schwab, M., Albino, AP and Old, LJ (1993) Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res, 53, pp. 3327-3335.
30. Rüger, R., Müller, D., Fahr, A. and Kontermann, RE (2005) Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes. J Drug Target, 13, pp. 399-406.
31. Rüger, R., Müller, D., Fahr, A. and Kontermann, RE (2006) In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes. J Drug Target, 14, pp. 576-582.
32. Siemann, DW, Chaplin, DJ and Horsman, MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer, 100, pp. 2491-2499.
33. Tahtis, K., Lee, F-T, Wheatley, JM, Garin-Chesa, P., Park, JE, Smyth, FE, Obata, Y., Stockert, E., Hall, CM, Old, LJ, Rettig, WJ and Scott, AM (2003) Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficiency mouse breast cancer xenograft model. Mol Cancer Ther, 2, pp. 729-737.
34. Völkel, T., Hölig, P., Merdan, T., Müller, R. and Kontermann, R. (2004) Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta, 1663, pp. 158-166.
35. Watermann, I., Gerspach, J., Lehne, M., Seufert, J., Schneider, B., Pfizenmaier, K. and Wajant, H. (2007) Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ, 14, pp. 765-774.